Texas-based gene therapy company Taysha Gene Therapies has announced an underwritten public offering of up to USD 75 million of common stock and pre-funded warrants. The company also granted underwriters a 30-day option to purchase 15% of the common shares.
The funds from the offering are intended to support the company's operations and development programs, though specific details were not provided. Other details, such as the size, closing date, and terms of the offering, were not disclosed.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.